Abstract Number: 2447 • ACR Convergence 2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…Abstract Number: 1517 • ACR Convergence 2024
Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico
Background/Purpose: The diagnosis of serositis in systemic lupus erythematosus (SLE) relies on combining clinical and serological data, alongside imaging studies. The aim of this study…Abstract Number: 2465 • ACR Convergence 2024
Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR
Background/Purpose: Interstitial lung disease (ILD) remains as the major driver of mortality in systemic sclerosis (SSc). The literature indicates that at the time of diagnosis…Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…Abstract Number: 1528 • ACR Convergence 2024
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…Abstract Number: 2492 • ACR Convergence 2024
ANCA Associated Tracheobronchial Disease
Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…Abstract Number: 2495 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…Abstract Number: 0714 • ACR Convergence 2024
Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an acutely life-threating presentation of ANCA-associated vasculitis (AAV), and patients with AAV are at increased risk of venous thromboembolic…Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »